Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
J Thorac Oncol. 2011 Aug;6(8):1359-66. doi: 10.1097/JTO.0b013e31821cfc73.
Accurate determination of ALK rearrangement is important in lung cancer patients, especially in determining their eligibility for crizotinib therapy. Fluorescence in situ hybridization (FISH) has been regarded as the gold standard method for detecting ALK rearrangement. However, FISH requires a fluorescence microscope, and the signals are labile and rapidly fade over time. This study evaluates the concordance between ALK gene rearrangement in non-small cell lung cancer assessed by ALK FISH and a newly developed ALK chromogenic in situ hybridization (CISH) and correlates the results with ALK protein expression assessed by immunohistochemistry.
A total of 465 formalin-fixed, paraffin-embedded non-small cell lung cancer samples were analyzed by ALK FISH (PathVysion, Vysis, Abbott) and ALK CISH. For comparison, all specimens were stained by immunohistochemistry (clone 5A4, Novocastra) and interobserver reproducibility was assessed.
We found that agreement between the pathologists on the CISH-determined ALK status was achieved in 449 patients (96.6%), and ALK rearrangement was identified in 18 patients (4.0%) in CISH method. Among these cases, 443 cases (95.3%) had results matching the corresponding FISH results: 17 rearranged, 425 wild types, and 1 discordant case. There was high concordance in the assessment of ALK gene rearrangement between FISH and CISH techniques (κ = 0.92) and between observers (κ = 0.97). In addition, there was high concordance in the ALK gene status and ALK protein expression between CISH and IHC tests (κ = 0.82).
CISH is a highly reproducible and practical method to detect ALK gene rearrangement and correlated well with ALK protein expression. Here, we present a diagnostic algorithm (Chung's SNUBH ALK protocol) to detect lung cancer with ALK rearrangements using IHC, FISH and CISH. Because CISH allows a concurrent analysis of histological features of the tumors and gene rearrangement, it appears to be a useful method in determining ALK gene rearrangement.
准确确定 ALK 重排对于肺癌患者非常重要,尤其是在确定他们是否适合克唑替尼治疗方面。荧光原位杂交(FISH)已被认为是检测 ALK 重排的金标准方法。然而,FISH 需要荧光显微镜,并且信号不稳定,随着时间的推移迅速衰减。本研究评估了非小细胞肺癌中通过 ALK FISH 评估的 ALK 基因重排与新开发的 ALK 显色原位杂交(CISH)之间的一致性,并将结果与通过免疫组织化学评估的 ALK 蛋白表达相关联。
对 465 例福尔马林固定、石蜡包埋的非小细胞肺癌样本进行了 ALK FISH(PathVysion,Vysis,Abbott)和 ALK CISH 分析。为了进行比较,所有标本均通过免疫组织化学(克隆 5A4,Novocastra)染色,并评估了观察者间的可重复性。
我们发现,病理学家在 CISH 确定的 ALK 状态上达成了 449 例患者(96.6%)的一致意见,并且在 CISH 方法中发现了 18 例患者(4.0%)的 ALK 重排。在这些病例中,443 例(95.3%)的结果与相应的 FISH 结果相匹配:17 例重排,425 例野生型,1 例不一致。FISH 和 CISH 技术之间(κ=0.92)以及观察者之间(κ=0.97)在评估 ALK 基因重排方面具有高度一致性。此外,CISH 和 IHC 检测之间在 ALK 基因状态和 ALK 蛋白表达方面具有高度一致性(κ=0.82)。
CISH 是一种高度可重复和实用的方法,可用于检测 ALK 基因重排,并与 ALK 蛋白表达密切相关。在这里,我们提出了一种使用 IHC、FISH 和 CISH 检测具有 ALK 重排的肺癌的诊断算法(Chung 的 SNUBH ALK 方案)。由于 CISH 允许同时分析肿瘤的组织学特征和基因重排,因此它似乎是一种确定 ALK 基因重排的有用方法。